Swiss biotech firm AC Immune said on Monday it had struck an exclusive worldwide license agreement potentially worth up to $509 million with Johnson & Johnson to develop so-called anti-Tau vaccines for Alzheimer's disease.
Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Shares of JNJ fell by 1.36% or $-1.45/share to $104.94. In the past year, the shares have traded as low as $86.09 and as high as $109.49. On average, 8268920 shares of JNJ exchange hands on a given day and today's volume is recorded at 7364760.
Source
